Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00269022 |
Despite the success of the triptan class of drugs, approximately 60% of patients who take medication at the moderate to severe pain stage of acute migraine, still have pain of mild or greater degree at 2 hrs post dose. SB-705498 is a novel, first in class TRPV1 receptor antagonist under development for the treatment of migraine pain. Preclinical experiments have demonstrated that the TRPV1 receptor is expressed both centrally and peripherally in the trigeminal system and inhibition of TRPV1 with SB-705498 can both prevent and reverse established central sensitisation.
Condition | Intervention | Phase |
---|---|---|
Migraine, Acute |
Drug: SB-705498 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Crossover Assignment, Efficacy Study |
Official Title: | A Single Blind, Placebo Controlled, Multi-Centre Study to Investigate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of the TRPV1 Antagonist SB-705498 Against the Pain of Acute Migraine. |
Estimated Enrollment: | 70 |
Study Start Date: | January 2006 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Australia, New South Wales | |
GSK Investigational Site | |
Randwick, New South Wales, Australia, 2031 | |
Canada, Ontario | |
GSK Investigational Site | |
Toronto, Ontario, Canada, M1L 4S4 | |
Netherlands | |
GSK Investigational Site | |
LEIDEN, Netherlands, 2333 ZA | |
United Kingdom, Cambridgeshire | |
GSK Investigational Site | |
Cambridge, Cambridgeshire, United Kingdom, CB2 2GG |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | SB-705498/008 |
Study First Received: | December 21, 2005 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00269022 |
Health Authority: | Australia: Therapeutic Goods Administration |
SB-705498
acute migraine
single dose
TRPV1
combination inpatient
outpatient study |
Migraine Disorders Headache Central Nervous System Diseases Headache Disorders, Primary |
Pain Brain Diseases Headache Disorders |
Nervous System Diseases |